Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

Printer friendly version
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
announced today that the following clinical and preclinical abstracts are expected
to be the subject of oral or poster presentations at the Annual Meeting of the
American Association for Cancer Research (AACR), being held April 12-16, 2008 in San
Diego:

    -- "Dendritic and T cell functions in patients with metastatic hormone-
       refractory prostate cancer treated with GVAX immunotherapy for prostate
       cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)
       - Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.

    -- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent
       induction of CD8+ T cell activation and clinical responses" (Abstract
       #2539, Clinical Immunotherapy Session) - Oral presentation scheduled
       for Monday, April 14, 2008 at 1:40 p.m.

    -- "Increased doses of an anti-CD30 antibody, MDX-060, results in
       prolonged progression free survival in subjects with CD30 positive
       lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,
       Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for
       Wednesday, April 16, 2008 at 8:00 a.m.

    -- "Preclinical development of anti B7-H4 therapeutic antibodies"
       (Abstract #4986, Developmental Immunotherapy Session) - Oral
       presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.

    -- "Human antibody conjugates of potential utility for prostate cancer
       therapy: a comparison of MGBA conjugates with antibodies targeting a
       cell surface target (prostate-specific membrane antigen) and an extra-
       cellular target (Mindin/RG1)" (Abstract #4062, Immunoconjugates,
       Peptides, and Protein Therapeutics Session) - Poster session scheduled
       for Tuesday, April 15, 2008 at 8:00 a.m.

    -- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"
       (Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics
       Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00
       a.m.

    -- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate
       and efficacy in a nude rat model of renal carcinoma" (Abstract #4057,
       Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster
       session scheduled for Tuesday, April 15, 2008 at 8:00 a.m.

    -- "Ptk7 as a direct and tumor stroma target in multiple solid
       malignancies" (Abstract #1526, Targets and Screening Approaches
       Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00
       p.m.

    Abstracts and information about the AACR and its Annual Meeting may be found at
www.aacr.org.

    About Medarex

    Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. More than 40 of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its website at
www.medarex.com.

    Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.

SOURCE  Medarex, Inc.
    -0-                             03/17/2008
    /CONTACT:  Laura S. Choi, Investor Relations, +1-609-430-2880, Ext. 2216, or
Jean Mantuano, Corporate Communications (media), +1-609-430-2880, Ext. 2221, both of
Medarex, Inc./
    /Company News On-Call:  http://www.prnewswire.com/comp/108265.html/
    /Web site:  http://www.medarex.com /
    (MEDX)

CO:  Medarex, Inc.; American Association for Cancer Research; AACR ST:  New Jersey,
California IN:  MTC BIO HEA SU:  TDS

AT-RF -- NEM046 -- 8551 03/17/2008 07:00 EDT http://www.prnewswire.com